Clinical Trials Directory

Trials / Completed

CompletedNCT02230904

A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease

A Multicenter, Randomized, Double-blind, 2-way Cross-over Study to Compare the Adhesiveness of 2 Different Rotigotine Patch Formulations in Subjects With Parkinson's Disease

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
57 (actual)
Sponsor
UCB BIOSCIENCES GmbH · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The primary objective of the study is to compare the adhesiveness of 2 different patch formulations of Rotigotine using the largest patch size of 40 cm\^2, under the assumption that both patch formulations show similar adhesiveness properties.

Conditions

Interventions

TypeNameDescription
DRUGRotigotine (Test product PR 2.3.1)* Pharmaceutical form: Transdermal patch * Concentration: 8 mg/24 hours * Route of administration: Transdermal
DRUGRotigotine (Reference product PR 2.1.1)* Pharmaceutical form: Transdermal patch * Concentration: 8 mg/24 hours * Route of administration: Transdermal

Timeline

Start date
2014-09-01
Primary completion
2014-11-01
Completion
2014-12-01
First posted
2014-09-03
Last updated
2015-11-02
Results posted
2015-11-02

Locations

11 sites across 1 country: Germany

Source: ClinicalTrials.gov record NCT02230904. Inclusion in this directory is not an endorsement.